Shots:

• The study will evaluate the safety and immunogenicity of GBP510 vs AZ/Oxford University’s COVID-19 vaccine and will enroll ~ 4-000 participants across multiple countries
• The initiation of the P-III study follows positive interim P-I/II data that showed all participants who received the GBP510 developed strong neutralizing Ab responses- demonstrating a 100% seroconversion rate
• The companies are planning for the global supply of the vaccine through the COVAX facility in the H1’22- subject to positive results and regulatory approval

  Ref: GSK | Image: GSK